[Experimental study of the anti-inflammatory action of pyridinolcarbamate].
When used in doses of 20-50 mg/kg on models of acute exudative and chronic propliferative inflammation in rats pyridinolcarbamate inhibited the development of an exudative reaction provoked by bradykinine and silver nitrate and did not influence the effects of histamine and dextran, nor the chronic proliferative inflammatory process. As concerns its antiexudative action pyridinolcarbamate is superior to butadion. The effect of the drug comes from its selective antibradykinine action.
D000818:Animals; D000893:Anti-Inflammatory Agents; D001920:Bradykinin; D002219:Carbamates / Q000627:therapeutic use*; D003911:Dextrans; D004353:Drug Evaluation, Preclinical; D006632:Histamine; D007249:Inflammation / Q000188:drug therapy*; D008297:Male; D011727:Pyridinolcarbamate / Q000627:therapeutic use*; D051381:Rats; D012835:Silver Nitrate
D000893:Anti-Inflammatory Agents; D002219:Carbamates; D003911:Dextrans; D011727:Pyridinolcarbamate; D006632:Histamine; D012835:Silver Nitrate; D001920:Bradykinin
Eksperimental'noe izuchenie protivovospalitel'nogo deĭstviia piridinolkarbamata